Skip to main content
Premium Trial:

Request an Annual Quote

Helomics GeneFx Colon

Helomics announced today the official launch of GeneFx Colon, its multi-gene expression assay designed to identify colon cancer patients who are at a higher risk of recurrence within five years following initial surgery. The test is intended to help physicians make informed personalized treatment decisions about potentially adding adjuvant chemotherapy.

GeneFx Colon is performed on a small amount of tumor tissue and test results are available within the average time period for recovery post-surgery. The assay produces a binary result that categorizes patients as being at either high- or low-risk for a tumor recurrence within five years.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.